Dizziness Handicap Inventory in Clinical Evaluation of Dizzy Patients

Zamysłowska-Szmytke, Ewa; Politański, Piotr; Józefowicz-Korczyńska, Magdalena

doi:10.3390/ijerph18052210

Cited by 42 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By objective genetic testing, our results revealed that the expression of all examined circadian clock genes did not significantly associate with DHI total score, as well as the physical, emotional and functional subscales scores in patients with MD. Our data imply that the dizziness handicap degree of MD is independent of circadian rhythm, but may be mainly influenced by the compensated and uncompensated status of vestibular dysfunction 48 …”

Section: Discussionmentioning

confidence: 65%

“…Our data imply that the dizziness handicap degree of MD is independent of circadian rhythm, but may be mainly influenced by the compensated and uncompensated status of vestibular dysfunction. 48 Within the postulated mechanisms behind the formation of endolymphatic hydrops in MD, oxidative stress of the inner ear was thought of as one of the causal factors. [49][50][51] Overproduction of reactive oxygen species is well known as the major contributor to the damage of hair cells in acquired hearing loss.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of circadian clock genes in leukocytes of patients with Meniere's disease

Yang

Hwang

Tsai

et al. 2022

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Objectives The underlying etiology of Meniere's disease (MD) is not completely clear, but the precipitated triggers may alter the circadian clock in patients with MD. This study aims to survey the expression of circadian clock genes in peripheral blood (PB) leukocytes of MD patients. Methods We investigated the expression of nine circadian clock genes in the PB leukocytes of patients with MD and normal controls using real‐time quantitative reverse transcriptase‐polymerase chain reaction (qRT‐PCR). Results We observed significantly lower expression of PER1 gene and higher expression of CLOCK gene in MD patients than those in normal controls (p < 0.05). PER1 did not associate with the degree of dizziness handicap in the patients with MD, but a lower expression of PER1 was significantly correlated with higher pure tone average (PTA) and speech reception threshold of the affected ear (p < 0.05). Patients with PTA > 30 dB had significantly lower PER1 expression than those with PTA ≤30 dB in the affected ear (p < 0.05). Our qRT‐PCR result was validated by fewer positively stained leukocytes for PER1 protein in the MD patients using the immunocytochemical study. Conclusion Our study implies the alteration of the circadian clock in patients with MD. In particular, the downregulation of PER1 correlated with the degree of hearing loss in the affected ear. PER1 in PB leukocytes may be a potential marker for the progression of hearing loss in MD.

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Expression of circadian clock genes in leukocytes of patients with Meniere's disease

Yang

Hwang

Tsai

et al. 2022

Laryngoscope Investig Oto

View full text Add to dashboard Cite

show abstract

“…The DHI is likely multidimensional in nature but that the dimensions are substantially different from the functional, emotional, and physical disability subscales. Items of the DHI do not evaluate the otological or neurovegetative symptoms which mostly accompany to vestibular symptoms, and do not assess the effects of dizziness on self-care activities [4,24].We only calculate the total scores, we should calculate subscale scores to assess the Physical manifestations, Catastrophic impact, and Emotional Impact of dizziness on the dizzy patient. PFO closure has demonstrated its effect in CS patients with PFO [25][26][27][28], and three randomized studies [29][30][31] and ve meta-analyses have addressed the issue of percutaneous closure as therapy for migraine [32][33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Relationship between Dizziness Handicap Inventory and Right to left shunt grading, and interventional therapy effect on unexplained dizziness: A prospective clinical study

Shen

Cao

et al. 2022

Preprint

View full text Add to dashboard Cite

Background and Objective: Unexplained dizziness remains a clinical challenge. Our previous studies have shown that unexplained dizziness may be related to patent foramen ovale (PFO). This study aims to explore whether the degree of shunt is correlated with the degree of unexplained dizziness and looking for the possible clinical intervention for patients with unexplained dizziness. Methods: This study was a large single-center, prospective, controlled study. From March 2019 to March 2022, patients with unexplained dizziness and explained dizziness and healthy controls were recruited. Contrast-enhanced transcranial Doppler sonography(c-TCD) was performed to detect the existence of right-to-left shunt (RLS) and shunt grading. The dizziness handicap inventory (DHI) was completed to evaluate the dizziness. Unexplained dizziness patients with large amount of PFO were volunteered to receive medication treatment and transcatheter PFO closure and followed up six months. Results: A total of 387 patients (132 unexplained, 123 explained and 132 controls) were enrolled. There was a statistical difference in the RLS grading with three groups (p < 0.001). The Spearman correlation coefficient of RLS grading and DHI scores in unexplained dizziness patients (r=0.122, p=0.163) and explained dizziness patients (r=0.067, p=0.460). In the unexplained group, there were 49 cases with massive grading RLS. Of which 25 patients received percutaneous PFO closure treatment and 24 cases received medication treatment. Followed up six months after treatment, the amount of DHI scores change in patients who received the percutaneous PFO closure was significantly higher than that in the medication treatment group (p < 0.001). Conclusion: RLS may play an important role in unexplained dizziness. For unexplained dizziness patients, PFO closure may contribute to better outcomes. In the future, large-scale randomized controlled studies are still needed.

show abstract

“…The score ranges from 0 (disabled) to 100 (very independent). The self-perceived level of handicap associated with the symptom of dizziness is measured by the 25-item Dizziness Handicap Inventory (DHI) [26]. Both ADL and GHI are self-report questionnaires.…”

Section: Data Collectionmentioning

confidence: 99%

Efficacy and safety of Dengyinnaotong Capsule in patients with Cognitive impairment caused by cerebral Small Vessel Disease: study protocol of a multicenter, randomized, open-label, controlled trial (De-CSVD trial)

Li¹,

Li²,

Tian³

et al. 2022

Trials

View full text Add to dashboard Cite

Background Cerebral small vessel disease (CSVD) is a common syndrome in the older population, with a prevalence ranging from 5% in subjects aged 50 years to almost 100% in those aged 90 years and older. It is regarded to be a major cause of vascular cognitive impairment. Existing prevention and treatment approaches have not yet shown ideal clinical outcomes. Dengyinnaotong Capsule has shown great potential for improving cognitive function. This trial (De-CSVD trial) is designed to investigate the efficacy and safety of Dengyinnaotong Capsule on cognitive function in patients with CSVD . Methods This multicenter, randomized, open-label, controlled trial is planned to recruit at least 270 patients with mild cognitive impairment related to CSVD in 25 centers in China. Recruitment started on 10 May 2021 and is foreseen to end on 31 December 2022. The final follow-up of participants will be completed by the end of March 2023. Participants will be randomized in a ratio of 1:1 to the experimental group (routine basic treatment plus Dengyinnaotong Capsule) or the control group (routine basic treatment). The primary outcome is the change in the Montreal Cognitive Assessment score from baseline to week 12. Secondary outcomes are changes in Shape Trail Test, Activities of Daily Living, Geriatric Depression Scale, and Dizziness Handicap Inventory score from baseline to week 12, new vascular events, and the changes in serum level of homocysteine, high-sensitivity C-reactive protein, and D-dimer from baseline to week 4 and 12, respectively. The exploratory outcome is the changes in the Tinetti performance-oriented mobility assessment score from baseline to week 12. Safety assessment is performed by monitoring vital signs, general biochemical examinations, 12-lead electrocardiogram examinations, and incidence of cardiovascular and cerebrovascular ischemia or bleeding events. Visits will be performed at week 0 (baseline, pre-randomization), week 4, and week 12 in the treatment period (post-randomization). Discussion This trial is the first to investigate the efficacy and safety of Dengyinnaotong Capsule on cognitive impairment in patients with CSVD. The findings of this study might provide convincing evidence regarding the efficacy of Dengyinnaotong Capsule in patients with mild cognitive impairment related to CSVD. Trial registration Chinese Clinical Trial Registry ChiCTR2100045831. Registered on 25 April 2021.

show abstract

Dizziness Handicap Inventory in Clinical Evaluation of Dizzy Patients

Cited by 42 publications

References 27 publications

Expression of circadian clock genes in leukocytes of patients with Meniere's disease

Expression of circadian clock genes in leukocytes of patients with Meniere's disease

Relationship between Dizziness Handicap Inventory and Right to left shunt grading, and interventional therapy effect on unexplained dizziness: A prospective clinical study

Efficacy and safety of Dengyinnaotong Capsule in patients with Cognitive impairment caused by cerebral Small Vessel Disease: study protocol of a multicenter, randomized, open-label, controlled trial (De-CSVD trial)

Contact Info

Product

Resources

About